Software company DocuSign’s (DOCU) stock scored a rating upgrade from Hold to Buy from William Blair, thanks to the optimism ...

Research analysts at William Blair issued their Q1 2026 earnings estimates for shares of argenx in a research note issued on ...

Equities researchers at William Blair issued their Q4 2026 earnings estimates for argenx in a report released on Monday, ...

Emerging markets present a landscape of opportunity for equity investors despite macroeconomic headwinds. Click to read.

Fintel reports that on March 17, 2025, William Blair upgraded their outlook for DocuSign (NasdaqGS:DOCU) from Market Perform ...

We recently published a list of 10 Worst High-Risk High-Reward Growth Stocks To Buy. In this article, we are going to take a ...

William Blair analyst Louie DiPalma maintained a Hold rating on Science Applications (SAIC – Research Report) today. The company’s shares ...

Fintel reports that on March 18, 2025, William Blair downgraded their outlook for Incyte (NasdaqGS:INCY) from Outperform to Market Perform. Analyst Price Forecast Suggests 28.39% Upside As of March 4, ...

The explosion of GLP-1 weight loss drugs is reminiscent of the early days of PD-1 inhibitors, but key market differences ...

We recently published a list of 11 Best Reddit Stocks to Invest In. In this article, we are going to take a look at where ...

Overall, Palantir has had a solid start to 2025. Its growth numbers look impressive, and its AI platform is gaining traction across industries. Yet not everyone is convinced. Some ...

The Maryland-based biopharma joins Eli Lilly and Novo Nordisk in trialing a GLP-1 agonist for alcohol- and liver-related ...